Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

Jan A. Burger(The University of Texas MD Anderson Cancer Center), Nicholas Chiorazzi(Feinstein Institute for Medical Research), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Naveen Garg(The University of Texas MD Anderson Cancer Center), Marc K. Hellerstein(Washington University in St. Louis), Shih‐Shih Chen(Feinstein Institute for Medical Research), Kelvin W. Li(KineMed (United States)), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Claire Emson, Mariela Sivina(The University of Texas MD Anderson Cancer Center), Ahmed M. Amer(Norwegian University of Science and Technology), Dominik Wodarz(University of California, Irvine), William G. Wierda(University of Maryland, Baltimore), Xiao‐Jie Yan, Susan O’Brien(University of California, Irvine), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), Scott Turner(KineMed (United States))
JCI Insight
January 25, 2017
10.1172/jci.insight.89904
Cited by 93

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k